Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.

Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care as well as the treatment of anemia, rheumatoid arthritis and other autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. Amgen continues to sustain a culture rooted in biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organization, we will follow the science wherever it may lead, to best treat serious illness.